×
About 28,403 results

ALLMedicine™ Acute Myeloid Leukemia Center

Research & Reviews  9,696 results

HLA-independent T cell receptors for targeting tumors with low antigen density.
https://doi.org/10.1038/s41591-021-01621-1
Nature Medicine; Mansilla-Soto J, Eyquem J et. al.

Jan 15th, 2022 - Chimeric antigen receptors (CARs) are receptors for antigen that direct potent immune responses. Tumor escape associated with low target antigen expression is emerging as one potential limitation of their efficacy. Here we edit the TRAC locus in h...

Levofloxacin prophylaxis for pediatric leukemia patients: Longitudinal follow-up for im...
https://doi.org/10.1002/pbc.29525
Pediatric Blood & Cancer; Davis A, Stevens AM et. al.

Jan 15th, 2022 - Bloodstream infections (BSIs) cause morbidity and mortality in pediatric patients with leukemia. Antibiotic prophylaxis during periods of chemotherapy-induced neutropenia may reduce the incidence of BSIs. A levofloxacin prophylaxis guideline was i...

Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia
https://clinicaltrials.gov/ct2/show/NCT02914977

Jan 14th, 2022 - Disease relapse remains the primary challenge in the treatment of acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). There is no standard of care treatment option for relapsed acute leukemia, and investigational therapies are recom...

Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT04867928

Jan 14th, 2022 - This is a phase 2, non-randomized, interventional, open-label, multicenter trial evaluating the efficacy of VEN-AZA as a bridge-to-transplant therapy in chemotherapy-treated adult NPM1mut AML patients who experience molecular relapse or progressio...

see more →

Guidelines  11 results

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
https://doi.org/10.6004/jnccn.2021.0002
Journal of the National Comprehensive Cancer Network : JN... Pollyea DA, Bixby D et. al.

Jan 7th, 2021 - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regard...

Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myel...
https://doi.org/10.1016/j.bbmt.2020.09.020
Biology of Blood and Marrow Transplantation : Journal of ... Dholaria B, Savani BN et. al.

Sep 24th, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
https://doi.org/10.6004/jnccn.2017.0157
Journal of the National Comprehensive Cancer Network : JN... Mesa RA, Jamieson C et. al.

Oct 7th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0116
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Jul 9th, 2017 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and p...

Acute myeloid leukemia, version 2.2013.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161234
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Sep 14th, 2013 - These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocyt...

see more →

Drugs  29 results see all →

Clinicaltrials.gov  551 results

Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia
https://clinicaltrials.gov/ct2/show/NCT02914977

Jan 14th, 2022 - Disease relapse remains the primary challenge in the treatment of acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). There is no standard of care treatment option for relapsed acute leukemia, and investigational therapies are recom...

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leuk...
https://clinicaltrials.gov/ct2/show/NCT04161885

Jan 14th, 2022 - The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Relapse Free Survival (RFS) in Acute Myeloid Leukemia (AML) participants compared to Best Supportive Care (BSC) when given as mai...

Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT04867928

Jan 14th, 2022 - This is a phase 2, non-randomized, interventional, open-label, multicenter trial evaluating the efficacy of VEN-AZA as a bridge-to-transplant therapy in chemotherapy-treated adult NPM1mut AML patients who experience molecular relapse or progressio...

Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine in Patients With Acute Myeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT03041688

Jan 13th, 2022 - PRIMARY OBJECTIVE: I. To evaluate the toxicities of navtemadlin (KRT-232 [AMG-232]) in combination with decitabine (20 mg/m^2 for 10 days), and to determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of KRT-232 (AMG-232) in c...

A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) (MK-0482-002)
https://clinicaltrials.gov/ct2/show/NCT05038800

Jan 13th, 2022 - The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and recommended Phase 2 dose (RP2D) of MK-0482. There are 2 parts of this study. Part 1 is a dose escalation which will follow an accelerated ti...

see more →

News  1,070 results

Innovative Center Focuses on Phase I Trials
https://www.onclive.com/view/innovative-center-focuses-on-phase-i-trials

Jan 3rd, 2022 - Angela Alistar, MD Medical Director Gastrointestinal Medical Oncology Morristown Medical Center A partnership between a healthcare system in Morristown, New Jersey, and a genomics research institute in Phoenix, Arizona, has led to the ope...

Luspatercept Shows Impressive Responses, Tolerability in Low-Risk MDS
https://www.onclive.com/view/luspatercept-shows-impressive-responses-tolerability-in-low-risk-mds

Dec 22nd, 2021 - Luspatercept-aamt (Reblozyl) produced more durable responses compared with placebo in patients with lower-risk myelodysplastic syndrome (LR-MDS) and anemia that is refractory to or ineligible for erythropoiesis-stimulating agent (ESA) therapy, acc...

Adaptation Is Key to Advancing Care for Adult Patients With Leukemia
https://www.onclive.com/view/adaptation-is-key-to-advancing-care-for-adult-patients-with-leukemia

Dec 21st, 2021 - It would be difficult to look at data involving practice-changing agents for patients with leukemia and miss the name Jorge E. Cortes, MD. An investigative leader for nearly 30 years, Cortes has led the development of numerous leukemia treatments,...

Sabatolimab Demonstrates Durable Clinical Benefits in Patients With AML, High-Risk MDS
https://www.onclive.com/view/sarbatolimab-demonstrates-durable-clinical-benefits-in-patients-with-aml-high-risk-mds

Dec 16th, 2021 - Sabatolimab (MBG453), an investigational TIM-3 monoclonal antibody, induced a median duration of response (DOR) greater than 1 year for patients with very high/high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) when used in ...

Maintenance Oral Azacitidine Shows Sustained Survival Benefit in AML in First Remission
https://www.onclive.com/view/maintenance-oral-azacitidine-shows-sustained-survival-benefit-in-aml-in-first-remission

Dec 14th, 2021 - The utilization of oral azacitidine as maintenance treatment in patients with acute myeloid leukemia (AML) in first remission following intensive chemotherapy continued to showcase a survival benefit over placebo, according to updated data from th...

see more →

Patient Education  4 results see all →